Predictive and prognostic factors in RCC

Poster Session 48

Sunday, 26 March
14:00 - 15:30

Location: Room 7, Capital suite (level 3)

Chairs: A. Mattei, Luzern (CH)
M. Oya, Tokyo (JP)
B. Peyronnet, Rennes (FR)

Aims and objectives of this session
To discuss various predictive and prognostic factors in RCC.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

640

Predictive factor of lymph node metastases in patients with non-metastatic renal cell carcinoma; multi-center study

Institutes: 1Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Dept. of Urology, 2Incheon, South Korea, 3St. Paul’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Dept. of Urology, 4Seoul, South Korea, 5Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea., Dept. of Urology, Bucheon, South Korea, 6Seoul National University College of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea, 7Chungbuk National University College of Medicine, Cheongju, Korea, Dept. of Urology, Cheongju, South Korea, 8Korea University School of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea, 9Seoul National University Bundang Hospital, Seongnam, Korea, Dept. of Urology, Seongnam, South Korea, 10College of Medicine, The Catholic University of Korea, Seoul, Korea, Dept. of Urology, Seoul, South Korea

641

Long-term assessment of mortality patterns after surgical treatment for non-metastatic kidney cancer: A competing risk analysis
By: Larcher A.1, Muttin F.1, Nini A.1, Trevisani F.1, Ripa F.1, Cianflone F.1, Carenzi C.1, Dell’Oglio P.1, Rigatti P.2, Dehó F.1, Montorsi F.1, Capitanio U.1, Bertini R.1

Institutes: 1IRCCS Ospedale San Raffaele, Urological Research Institute, Division of Oncology, Unit of Urology, Milan, Italy, 2Scientific Institute Istituto Auxologico Italiano, Department of Urology, Advanced Urotechnology Center, Milan, Italy

642

External validation of the Mayo Clinic Stage, Size, Grade, and Necrosis score in patients with renal cell carcinoma and venous tumor thrombus

Institutes: 1Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, 2University of California, Dept. of Epidemiology and Biostatistics, San Francisco, United States of America, 3University of California-Davis, Dept. of Urology, Sacramento, United States of America, 4University of California-San Diego, Dept. of Urology, Madrid, Spain, 5University of Miami, Dept. of Urology, Miami, United States of America, 6University of Southern California, Dept. of Urology, Los Angeles, United States of America, 7University of California-Davis, Dept. of Urology, Sacramento, United States of America, 8University of Turin, Dept. of Urology, Turin, Italy, 9University of Frankfurt, Dept. of Urology, Frankfurt, Germany, 10University of Heidelberg, Dept. of Urology, Heidelberg, Germany, 11New York University School of Medicine, Dept. of Urology, New York, United States of America, 12New York University School of Medicine, Dept. of Urology, New York, United States of America,
The prevalence of renal cancer detected by abdominal ultrasonography in asymptomatic individuals: A systematic review and meta-analysis to inform the case for a screening study

By: Rossi S.1, Hsu R.1, Blick C.2, Goh V.2, Hanbury D.4, Nathan P.3, Nicol D.6, Fleming S.1, Sweeting M.1, Watson C.4, Wilson E.10, Stewart G.1

Institutes: 1Addenbrooke’s Hospital, Dept. of Urology, Cambridge, United Kingdom, 2Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, 3Guy’s & St Thomas’ Hospitals NHS Trust, Dept. of Radiology, London, United Kingdom, 4Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, 5Mount Vernon Cancer Centre, Dept. of Oncology, Northwood, United Kingdom, 6Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, 7Ninewells Hospital, Centre for Forensic and Legal Medicine, Dundee, United Kingdom, 8University of Cambridge, Dept. of Public Health and Primary Care, Cambridge, United Kingdom, 9National Cancer Research Institute, Renal and Bladder Cancer Clinical Studies Group, London, United Kingdom, 10University of Cambridge, Cambridge Centre for Health Services Research, Cambridge, United Kingdom

Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma

By: Pecoraro A.1, Larcher A.1, Nini A.1, Muttini F.1, Stabile A.1, Di Trapani E.1, Carenzi C.1, Trevisani F.1, De Cobelli F.2, Gaboardi F.1, Guazzoni G.3, Briganti A.1, Pascual A.1, Montorsi F.1, Bertini R.1, Capitanio U.1

Institutes: 1IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Oncology and Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy, 3Humanitas Clinical and Research Centre, Dept. of Urology, Milan, Italy

Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: Results of an international multi-institutional study on 2189 patients


Institutes: 1University Hospital Mainz, Dept. of Urology, Mainz, Germany, 2University Hospital Barcelona, Dept. of Urology, Barcelona, Spain, 3Medical University of Vienna, Dept. of Urology, Vienna, Austria, 4Instituto Nacional De Cancerologia, Dept. of Urology, Mexico, Mexico, 5Carl-Thiem-Klinikum Cottbus, Dept. of Urology, Cottbus, Germany, 6Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, 7University of Muenster Medical Center, Dept. of Urology, Muenster, Germany, 8Hospital Bad Saarow, Dept. of Urology, Bad Saarow, Germany, 9Julius–Maximilians–University Medical Centre of Würzburg, Dept. of Urology, Würzburg, Germany, 10University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, 11University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 12University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany, 13Fundeni Clinical Institute, Centre of Urological Oncology, Dialysis and Renal Transplantation, Bucharest, Romania, 14University of Pilsen, Dept. of Urology, Pilsen, Czech Republic, 15Medical University Graz, Dept. of Urology, Graz, Austria, 16Klinikum St. Elisabeth Straubing, Dept. of Urology, Straubing, Germany, 17Ludwig–Maximilians–University, Dept. of Urology, Munich, Germany

Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease

By: Wagener N.1, Edelmann D.2, Benner A.2, Huck N.1, Hutterer G.3, Zigeuner R.3, Borgmann H.4, Haferkamp A.5, Pahernik S.5, Wolff I.5, Krabbe L.M.7, Herrmann E.7, Vergho D.5, Mirvald C.9, Surcel...
Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes – a RECUR database analysis

By: Dabestani S.¹, Beisland C.², Gudmundsson E.³, Stewart G.⁴, Lam T.⁵, Gietzmann W.⁶, Zakikhani P.⁷, Marconi L.⁸, Williams S.⁹, Powles T.⁹, Van Werkhoven E.⁹, Meijer R.P.¹², Ljungberg B.¹¹, Bex A.¹⁰

Institutes: Lund University, Dept. of Clinical Sciences, Malmö, Sweden, ²Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ³Landspitali University Hospital, Dept. of Urology, Reykjavik, Iceland, ⁴University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, ⁵University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ⁶Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, ⁷Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal, ⁸Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, ⁹The Netherlands Cancer Institute, Dept. of Bioinformatics and Statistics, Amsterdam, The Netherlands, ¹⁰The Netherlands Cancer Institute, Division of Surgical Oncology, Department of Urology, Amsterdam, The Netherlands, ¹¹Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, ¹²University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, ¹³University of Edinburgh, Dept. of Urology, Edinburgh, United Kingdom

Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis

By: Gild P.¹, Von Landenberg N.¹, Sun M.¹, Develasco G.², Brastianos P.³, Menon M.⁴, Fisch M.⁵, Chun F.⁶, Nguyen P.⁷, Trinh Q-D.⁸, Choueiri T.²

Institutes: Brigham and Women’s Hospital, Center For Surgery and Public Health and Division of Urologic Surgery, Boston, United States of America, ¹Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, ²Dana-Farber Cancer Institute, Dept. of Cancer Biology, Boston, United States of America, ³Henry Ford Hospital, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, ⁴University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁵Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Dept. of Medical Oncology, Boston, United States of America

Utilization and outcomes of T2 partial nephrectomy: A US population based analysis of the national cancer database

By: Hamilton Z., Fero K., Bloch A., Field C., Han D., Derweesh I.

Institutes: Moores Cancer Center, Dept. of Urology, La Jolla, United States of America

Contact with renal sinus is a significant risk factor for metastasis in pT1 clear cell renal cell carcinoma
carcinoma
By: Izumi K.¹, Saito K.¹, Nakayama T.¹, Fukuda S.², Fukushima H.³, Uehara S.⁴, Koga F.³, Yonese J.⁴, Kageyama Y.², Kihara K.⁵, Fujii Y.⁵
Institutes: ¹Tokyo Medical And Dental Graduate School, Dept. of Urology, Tokyo, Japan, ²Saitama Cancer Center, Dept. of Urology, Saitama, Japan, ³Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan, ⁴Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, ⁵Tokyo Medical and Dental Graduate School, Dept. of Urology, Tokyo, Japan

651
Utility of chest x-ray in follow-up of pT1 renal cell carcinoma
By: Rizzo M.¹, Umari P.¹, Pavan N.¹, Liguori G.¹, Verzotti E.¹, Cancellieri L.¹, Mottrie A.², Minervini A.³, Trombetta C.³
Institutes: ¹Cattinara Hospital; University of Trieste, Dept. of Urology, Trieste, Italy, ²Onze-Lieve-Vrouweziekenhuis, Dept. of Urology, Aalst, Belgium, ³University Hospital Careggi, Dept. of Urology, Florence, Italy

652
Organ confined renal cell carcinoma - are the current guidelines sufficient?
By: Frees S.¹, Kamal M.¹, Nestler S.², Bidnur S.³, Levien P.¹, Neisius A.¹, Jaeger W.¹, Thomas C.¹, Thüroff J.⁴, Roos F.¹
Institutes: ¹University Medical Center, Dept. of Urology, Mainz, Germany, ²Hochtaunus Hospital Bad Homburg, Dept. of Urology, Bad Homburg, Germany, ³Vancouver Prostate Center, Dept. of Urology, Vancouver, Canada, ⁴University Medical Center, Dept. of Urology, Mannheim, Germany

653
Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy results: A multicenter study
By: Tondut L.¹, Peyronnet B.¹, Bernhard J-C.², Vaessen C.³, Doumerc N.⁴, Sebe P.⁵, Pradere B.⁶, Guillonneau B.⁷, Nouhaud F.X.⁷, Brichart N.⁸, Alimi Q.¹, Beauval J-B.⁹, Rammal A.⁹, De La Taille A.¹⁰, Baumert H.¹¹, Droupy S.¹², Bruyere F.⁶, Roupret M.³, Mejean A.¹³, Bensalah K.¹

654
Hospital activity and costs following partial nephrectomy: A comparison of surgical modalities using UK data
By: Camp C.¹, O’Hara J.², Hughes D.¹, Adshead J.²
Institutes: ¹Hcd Economics, Dept. of Economics, Daresbury, United Kingdom, ²Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Dept. of Urology, Stevenage, United Kingdom